Author

Crippa JAS

Faculdade de Medicina de Ribeir

Biography

Crippa JAS is working as professor in Neuroscience and Behavior Department, Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil. Research experience includes various programs, contributions and participation in different countries for diverse fields of Anxiety, Childhood Disorders, Depression and Aging, Mood Disorders and Post Traumatic Disorders.
Title
Cited by
Year
Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during …
JAS Crippa, AW Zuardi, FS Guimarães, AC Campos, F de Lima Osório, ...JAMA network open 4 (8), e2120603-e2120603, 2021202
44
2021
Cannabidiol for rapid eye movement sleep behavior disorder
CMO de Almeida, MMC Brito, NB Bosaipo, AV Pimentel, V Tumas, ...Movement Disorders 36 (7), 1711-1715, 2021202
32
2021
Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE Study): a randomized, double-blind, placebo-controlled clinical trial
JAS Crippa, JC Pacheco, AW Zuardi, FS Guimarães, AC Campos, ...Cannabis and Cannabinoid Research 7 (5), 658-669, 2022202
23
2022
Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors
GK Silva-Cardoso, W Lazarini-Lopes, JE Hallak, JA Crippa, AW Zuardi, ...Neuropharmacology 197, 108712, 212
20
2021
The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event
LM Bolsoni, JAS Crippa, JEC Hallak, FS Guimaraes, AW ZuardiBrazilian Journal of Psychiatry 44, 298-307, 2022202
12
2022
Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic
JC Pacheco, JDS Souza, JEC Hallak, F de Lima Osório, AC Campos, ...Journal of Clinical Psychopharmacology 41 (3), 327-329, 2021202
12
2021
Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
JFC Pedrazzi, AJ Sales, FS Guimarães, SRL Joca, JAS Crippa, E Del BelProgress in Neuro-Psychopharmacology and Biological Psychiatry 1, 0352, 2021202
11
2021
Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder
LM Bolsoni, JAS Crippa, JEC Hallak, FS Guimarães, AW ZuardiPsychopharmacology 239 (5), 1499-1507, 2022202
10
2022
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli
N Abichabki, LV Zacharias, NC Moreira, F Bellissimo-Rodrigues, ...Scientific reports 12 (1), 6454, 2022202
9
2022
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic
JDS Souza, AW Zuardi, FS Guimarães, FL Osório, SR Loureiro, ...Frontiers in Pharmacology 13, 5646, 2022202
8
2022
Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification
PGP Rosa, A Zugman, CT Cerqueira, MH Serpa, FL de Souza Duran, ...Schizophrenia research 236, 104-114, 2021202
8
2021
Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters
JA Crippa, LC Pereira, LC Pereira, PM Zimmermann, J Liberato Brum, ...Brazilian Journal of Psychiatry 44 (1), 15, 2022202
7
2022
Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Efficacy and safety of cannabidiol plus …
JAS Crippa, AW Zuardi, FS Guimarães, AC Campos, F de Lima Osório, ...JAMA Netw Open 4 (8), e2120603, 2021202
7
2021
Case report: cannabidiol-induced skin rash: a case series and key recommendations
JDS Souza, M Fassoni-Ribeiro, RM Batista, JM Ushirohira, AW Zuardi, ...Frontiers in Pharmacology 13, 88117, 2022202
6
2022
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized …
RG Dos Santos, JM Rocha, GN Rossi, FL Osório, G Ona, JC Bouso, ...Human Psychopharmacology: Clinical and Experimental 37 (4), e2834, 2022202
5
2022
Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study
D de Paula Faria, L Estessi de Souza, FLS Duran, CA Buchpiguel, ...International Journal of Molecular Sciences 23 (3), 1076, 2022202
5
2022
Adverse Effects of oral cannabidiol: an updated systematic review of Randomized controlled trials (2020–2022)
JDR Souza, JC Pacheco, GN Rossi, BO de-Paulo, AW Zuardi, ...Pharmaceutics 14 (12), 298, 2022202
5
2022
Monitoring the mental health and professional overload of health Workers in Brazil: a longitudinal study considering the first wave of the COVID-19 pandemic
FL Osório, AW Zuardi, ILM Silveira, JAS Crippa, JEC Hallak, ...Frontiers in Psychiatry 13, 852157, 2022202
4
2022
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
JFC Pedrazzi, FR Ferreira, D Silva-Amaral, DA Lima, JEC Hallak, ...Psychopharmacology 239 (9), 2713-273, 2022202
4
2022
Endocannabinoid system attenuates oxaliplatin-induced peripheral sensory neuropathy through the activation of CB1 receptors
AF Pereira, MRP Lisboa, BW de Freitas Alves, CMP da Silva, DBS Dias, ...Neurotoxicity Research 39 (6), 1782-1799, 2021202
4
2021

Referred From: https://scholar.google.com/citations?user=oundwuMAAAAJ&hl=en

Cited by
Citations 28740
h-index 89
i10-index 316
Recommended Journals
Open Access Journals